News

Filter

Current filters:

Firazyr

Shire strengthens position in rare diseases with $4.2 billion buy of ViroPharma

Shire strengthens position in rare diseases with $4.2 billion buy of ViroPharma

11-11-2013

Ireland-based drugmaker Shire saw its share rise 2.2% to £33.16 shortly after markets opened this morning,…

CinryzeFirazyrMergers & AcquisitionsPharmaceuticalRare diseasesShireViroPharma

US FDA approves Shire’s Firazyr to treat acute attacks of hereditary angioedema

26-08-2011

After a near unanimous recommendation from an advisory panel earlier this year (The Pharma Letter June…

FirazyrNorth AmericaPharmaceuticalRare diseasesRegulationShire

FDA advisory panel backs approval of Shire’s Firazyr for HAE; Replagal site cleared by EMA

27-06-2011

In a decision that was largely expected given positive briefing papers by US Food and Drug Administration…

BiotechnologyFirazyrNorth AmericaPharmaceuticalRare diseasesRegulationReplagalShire

Shire presents new data for Replagal and VPRIV; gets PUDFA date for Firazyr

22-03-2011

Ireland-headquartered biopharma company Shire (LSE: SHP) presented new data for Replagal (agalsidase…

FirazyrPharmaceuticalRare diseasesRegulationReplagalResearchShireVpriv

EU Commission OKs InterMune's Esbriet and self-admin label for Shire's Firazyr

04-03-2011

In a batch of new drug approvals, the European Commission provided a boost to InterMune and Shire clearing…

EsbrietFirazyrInterMuneOncologyPharmaceuticalPromediorRare diseasesRegulationResearchShire

Shire gains extended US approval ADHA drug for Intuniv; files response on Firazyr

02-03-2011

Ireland headquartered specialty drugmaker Shire (LSE: SHP) has received US Food and Drug Administration…

FirazyrIntunivNeurologicalNorth AmericaPharmaceuticalRare diseasesRegulationShire

COMPANY SPOTLIGHT

Menarini

Back to top